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Abstract 
Bexarotene has been reported to reduce brain amyloid-β (Aβ) levels and to improve cognitive 
function in transgenic mouse models of Alzheimer’s disease (AD). Four groups failed to fully 
replicate the primary results but the original authors claimed overall support for the general 
conclusions. Because of its potential clinical importance, the current work studied the effects 
of bexarotene using two animal species and highly relevant paradigms. Rats were tested for 
the ability of bexarotene to prevent changes induced by an Aβ challenge in the form 
intracerebroventricular (i.c.v) administration of 7PA2 conditioned medium (7PA2 CM) 
which contains high levels of Aβ species. Bexarotene had no effect on the long-term 
potentiation of evoked extracellular field excitatory postsynaptic potentials induced by i.c.v. 
7PA2 CM. It also had no effect following subcutaneous administration of 2, 5, 10 and 15 
mg/kg on behavioral/cognitive impairment using an alternating-lever cyclic-ratio schedule of 
operant responding in the rat. The effects of bexarotene were further tested using the 
APPSwFILon,PSEN1*M146L*L286V transgenic mouse model of AD, starting at the time 
Aβ deposits first begin to develop. Mice were sacrificed after 48 days of exposure to 100 mg 
bexarotene per day. No significant difference between test and control mice was found using 
a water-maze test, and no significant difference in the number of A deposits in cerebral 
cortex, using two different antibodies, was apparent. These results question the potential 
efficacy of bexarotene for AD treatment, even if instigated in the preclinical period prior to 
the onset of cognitive deficits reported for human AD. 
 
KEY WORDS: Bexarotene; Alzheimer’s disease; Beta-amyloid; Oligomers; Synaptic 
transmission; Behavior. 
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 1. Introduction 
Cramer et al. (2013) reported that bexarotene (Bex) administration rapidly decreased Aβ1-
40 and Aβ1-42 interstitial fluid levels in the brains of two month old PPswe/PS1Δe9 (APP/PS1) 
transgenic (Tg) mice - a well-studied Tg mouse model of Alzheimer’s disease (AD). The 
effect was seen within 6 hours of administration, and there was a 25% reduction of Aβ by 24 
hours. A single dose of 100 mg/kg orally was reported to maintain the effect for 70 hours, 
and a similar outcome was found in normal (non-Tg) C57B1/6 mice. It was further reported 
that acute administration of Bex resulted in the rapid elimination of both diffuse and compact 
Aβ plaques in the cortex and hippocampus of the APP/PS1 mice. In 11 month old APP/PS1 
mice, Bex administration for 7 days produced significantly reduced levels of soluble and 
insoluble Aβ1-40 and Aβ1-42, resulting in a 50% reduction in Aβ plaque numbers. 
Behaviourally, Bex was reported to restore cognition and memory in APP/PS1, APPPS1-21 
and Tg2576 Tg mice. In addition, 90 days of Bex administration in APP/PS1 mice, and 20 
days of administration in APPPS1-21 mice induced improved hippocampal function, as 
measured using a contextual fear conditioning task and a water maze task. Also, nest 
construction in the Tg2576 Tg mouse was restored after 72 hours of Bex administration, and 
odor habituation behavior was improved after 9 days of Bex administration when given to 12 
and 14 month old mice. These findings implied that even acute administration of Bex to AD 
patients might be effective in treating both the early and late stages of AD. 
Four independent research groups have already questioned these findings. Fitz et al., 
(2013), while confirming the observation of reversal of memory deficits and the decrease in 
interstitial fluid Aβ levels following Bex administration, found no effect on brain Aβ 
deposition. Veeraraghavalu et al. (2013) also found no effect of Bex in reducing the Aβ 
plaque burden in APP/PS1, 5XFAD, and APPPS1-21 mice. Price et al. (2013), using an 
almost identical treatment regimen to Cramer et al. (2013) were unable to find any evidence 
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for positive effects of Bex. Tesseur et al. (2013) using mice and dogs, also could not fully 
replicate the reported effects of Bex administration. All of these studies involved 
administering single doses or very short term daily doses of Bex by oral gavage. Shortly 
after, a further group using an almost identical treatment regimen was unable to find any 
evidence for positive effects of Bex (LaClair et al., 2013). In response to these reports, the 
original authors stated their data “replicate and validate our central conclusion that 
bexarotene stimulates the clearance of soluble -amyloid peptides and results in the reversal 
of behavioral deficits in mouse models of Alzheimer’s disease” (Landreth et al., 2013). 
Because of the obvious lack of unambiguous confirmation of the effects of Bex relative to 
the treatment of AD, and the potential that the original report might have for clinical 
applications, we have further investigated the effects of Bex using more thorough paradigms. 
Two animal species and different but highly relevant models of AD were employed. One of 
the species utilized was normal male Sprague-Dawley rats. We administered into freely 
moving normal rats conditioned medium (CM) from 7PA2 cells by intracerebroventricular 
(i.c.v.) injection. 7PA2 CM expresses human amyloid precursor protein and secretes Aβ 
oligomers, dimers, trimers and tetramers (Podlisny et al., 1995; Podlisny et al., 1998; Walsh 
et al., 2002; Walsh et al., 2005). The CM contains a total human Aβ concentration in the 
pg.ml
-1 
range, which is similar to that found in human CSF (Podlisny et al., 1998). The i.c.v. 
7PA2 CM injection model has consistently been shown to impair LTP in experimental 
animals (e.g., Walsh et al., 2002; Townsend et al., 2006; O’Hare et al., 2013), and is therefore 
highly suitable to test any ameliorative effects of Bex on synaptic transmission. Effects were 
measured by recording long-term potentiation (LTP) of evoked extracellular field excitatory 
postsynaptic potentials (fEPSPs) in the CA1 region of hippocampal slices. The i.c.v. 7PA2 
CM injection model has also consistently been shown to detrimentally affect memory-related 
behavior in the rat under an alternating-lever cyclic-ratio (ALCR) schedule of food 
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reinforcement (e.g., Cleary et al., 2005; Poling et al., 2008; Reed et al., 2011). Consequently, 
this method was used to assess the effect of Bex on behavior/cognition following 
subcutaneous (s.c.) administration of 2, 5, 10 and 15 mg/kg Bex in the rat. 
The second species used was Tg mice. Tg AD mouse models have become a standard for 
screening potential pharmacological agents to treat AD. They have in common the 
introduction of one or more transgenes that enhance the production of human Aβ species.  In 
view of the dramatic effects of Bex as reported by Cramer et al. (2013), it seemed appropriate 
to test the effects of Bex over time using an aggressive Tg mouse model of AD. The Jackson 
Laboratory Tg model of AD, APPSwFILon,PSEN1*M146L*L286V (Jackson Laboratory, 
Bar Harbor, ME, USA; B6SJSL) was employed as it is the most aggressive Tg mouse model 
of AD so far developed. Bex treatment was instigated at 7-8 weeks of age, when Aβ deposits 
first begin to develop in this model of AD. This would be analogous to treating AD cases in 
the preclinical phase of the disease, before cognitive deficits appear. Chronic administration 
of a very high dose of Bex (ca. 100 mg/kg/d) was used, as early treatment with such a high 
dose would be the best way of determining if Bex could have a preventative effect on Aβ 
accumulation and subsequent AD pathology. No ameliorative effects of Bex was found in 
any of the rat models (electrophysiological and behavioral), or mouse models (behavioral and 
histopathological) employed in the studies conducted. 
 
2. Methods 
2.1 7PA2 cells 
7PA2 cells are stably transfected Chinese hamster ovary (CHO) cells which incorporate 
the cDNA for APP (APP751). This is specific for the familial AD mutation Val1717Phe 
(Podlisny et al., 1998; Shankar et al., 2011). The cells secrete Aβ1-40 and Aβ1-42 (Shankar et 
al., 2011). These cells were grown to just below confluence in DMEM containing 10% FBS 
Neuropharmacology     
7 
 
and 200 µg/ml G418.  They were briefly washed in DPS and incubated at 37ºC with 5% CO2 
for 18 h with a sufficient volume of DMEM to cover the cells. After incubation, the medium 
was centrifuged at 3000 g for 15 min and either used directly or snap frozen and stored at -
20ºC for later use. Using ELISA methodology, the concentration of total Aβ in the 7PA2 CM 
was in the range of 2-5 nM. 
 
2.2 Animals 
All animals were held in vivaria with automatically controlled temperature 
maintained at 23 ºC under a 12 h light/dark schedule (lights on at 0800 h). Specific details are 
given below for each manipulation. The animal experiments were conducted with the 
approval of the appropriate institutional ethics committees, and approved by the Animal Use 
Protocol 09-AOU-E-033 Canada, and license from the United Kingdom Home Office. 
 
2.3 LTP 
Evoked extracellular field excitatory postsynaptic potentials (fEPSPs) were recorded from 
400 µm para-sagittal hippocampal slices prepared from male Sprague-Dawley rats (Charles 
River, Canada). After a 1 h recovery period at room temperature in artificial cerebrospinal 
fluid (aCSF; composition in mM: NaCl 127, KCl 1.6, KH2PO4 1.24, MgSO4 1.3, CaCl2 2.4, 
NaHCO3 and D-glucose 10), the hippocampal slices were transferred to an interface chamber 
warmed to 30 ± 1ºC and perfused with aCSF. Schaffer collateral fibres were stimulated every 
30 sec using a concentric bipolar electrode (FHC, USA) and evoked fEPSPs were recorded 
from the stratum radiatum of the CA1 region of the hippocampus. Stimulation intensity was 
set to evoke fEPSPs of 30-40% of the maximum amplitude. A 10 min stable baseline was 
recorded and thereafter the test substances were administered in aCSF for a 30 min period, 
prior to high frequency stimulation (HFS; 100 Hz for 1 sec) of the Schaffer collateral 
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pathway. The test substances used were 7PA2 CM (challenge) and CHO CM (wild-type 
control). Bex (Sigma, UK) was the test substance and DMSO the control vehicle. Bex was 
diluted with aCSF immediately prior to application to the hippocampal slices, giving final 
concentrations of 20 µM Bex and 0.1% DMSO. fEPSPs were recorded for 60 min after HFS 
stimulation, and the final 10 min of recording (20 sweeps) was used for group comparisons of 
LTP magnitude using a one-way ANOVA and Dunnett’s post hoc test. 
 
2.4 Operant behavior test 
Behavioral data were collected using the ALCR schedule. Male Sprague-Dawley rats, 
weighing 220-250 g at the beginning of the experiment were maintained at 90% of their free-
feeding body weights and housed individually with water available ad libitum. The rats were 
trained and tested in two-lever rat test chambers (Med Associates Inc., USA) enclosed in 
sound attenuating compartments. Food reinforcers were 45 mg sucrose pellets (BioServ, 
USA), that were delivered into a tray situated midway between the two operant response 
levers. The training regimen has been previously reported (Cleary et al., 2005; Reed et al., 
2011). Briefly, operant behavioral sessions were conducted 7 d/wk and the rats were trained 
to press both levers for food reinforcement. Over approximately 20-30 sessions, the ALCR 
schedule of food reinforcement was introduced. Under this behavioral assay, rats must 
alternate to the other lever after pressing the currently correct lever a sufficient number of 
times to obtain a reinforcer. The number of lever presses required for each reinforcer 
changes, increasing sequentially from 2 responses per food pellet to 56 responses per food 
pellet, then decreasing sequentially from 56 responses per food pellet back to 2, and this 
sequence is repeated over 6 cycles. One complete cycle (of the 6) requires alternating lever 
responses of 2, 6, 12, 20, 30, 42, 56, 56, 42, 30, 20, 12, 6, and 2. This provides a measure of 
short-term memory, and generates data on two types of errors. These are lever-switching 
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errors, which occur when a subject (rat) fails to alternate between the two levers after being 
reinforced and continues to press the lever that produced the immediate food reinforcer 
(short-term memory error), and incorrect-lever perseverations. Perseverative behavior has 
been suggested to be an indicator of early AD (Traykov et al., 2005). This occurs when a 
subject continues to press the incorrect lever after making a lever-switching error (thus 
compounding the short-term memory error). This type of error indicates disruption of well-
learned behaviors, or reference (long-term) memory, which includes reasoning and the goal-
oriented manipulation of information. 
When the ALCR schedule reflected no changes in operant response trends, the rats were 
anaesthetized using fentanyl citrate inhalation (0.4 ml/kg). They were placed in a stereotaxic 
frame (Kopf, USA), and fitted with a permanently indwelling cannula (23 gauge) aimed at 
the lateral cerebral ventricle. Half of the rats in each group received left lateral ventricle 
cannula implants and the other half received right lateral ventricle cannula implants. With the 
incisor bar set 3 mm below the interaural line, stereotaxic co-ordinates for cannula 
implantation were; bregma -1.0 mm, -1.5 mm lateral to the midline, and 3 mm below the pial 
surface (Paxinos and Watson, 1998). All rats were allowed 7 d for recovery before 
experimental testing. Prior to being assigned to a control or experimental group, the i.c.v. 
cannula placement and its patency was verified by vigorous drinking (>5 ml/20 min) 
following i.c.v. injection of 0.5 µg/ml of angiotensin II (Johnson and Epstein, 1974). The rats 
were then randomly assigned to control or experimental groups consisting of 12 animals per 
group. To establish response parameters in the absence of induction of a behavioral deficit 
through i.c.v. injection of 7PA2 CM, or of Bex administration, an overall control group was 
injected i.c.v. with CHO CM (wild-type control; 10 µl), then after 1 h was injected 
subcutaneously (s.c.) with 1% DMSO, and 1 h later tested using the ALCR schedule. A 
second control group, against which Bex effects would be measured, was injected i.c.v. with 
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7PA2 CM (10 µl), then injected s.c. after 1 h with 1% DMSO, and 1 h later tested using the 
ALCR schedule. This temporal sequence for behavioral testing 2 h following i.c.v. injection 
of 7PA2 CM has been previously described (e.g., Cleary et al., 2005). For the determination 
of Bex effects, separate groups were injected i.c.v. with 7PA2 CM (10 µl), then injected s.c. 
after 1 h with 2.5, 5, 10, or 15 mg/kg Bex.  One h later they were tested using the ALCR 
schedule. Data were analyzed by one-way ANOVA, followed by Fisher’s Post-Hoc Least 
Significant Differences tests. 
 
2.5 Transgenic Mice 
5XFAD (APPSwFILon, PSEN1*M146L*L286V) (B6JSL) mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME, USA). The mice were divided into two groups. 
The control group (n=7) were fed normal chow and the test group (n=8) were fed chow 
containing 500 mg/kg Bex starting at 7-8 weeks of age, when Aβ deposits first begin to 
accumulate. Based on mouse weight and average food consumption, this corresponded to an 
oral dose of 2 mg per day, or 100 mg/kg/day. One mouse from each group was sacrificed at 
20 days and one at 30 days for assessment of the accumulation of Aβ deposits. The remainder 
was sacrificed 48 days after commencement of Bex feeding. One week prior to sacrifice, 
animals from both groups were assessed for memory-related effects using a standard water 
maze test. 
 
2.6 Water maze test 
The water maze was set up in a pool 1.5 meters in diameter. A 10 cm diameter 
platform was placed in the south eastern quadrant of the pool. The mice were placed in the 
pool and required to swim to the platform. The training procedure consisted of a one day test 
where the platform was visible, followed by 4 days where an opaque fluid was used, so that 
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the platform was invisible. In the visible platform test, the mice received 5 contiguous trials, 
with an inter-trial interval of 30 min. In the hidden platform test, the mice were trained for 6 
trials, with an inter-trial interval of 1 h. A probe trial was carried out 24 h after the last hidden 
platform test. Tracking of mouse movement was conducted with ANY-maze AVI recorder 
(Stoelting Co., IL, USA). Data were analyzed by two-way ANOVA. 
 
2.7 Mouse immunohistichemistry 
Immunohistochemistry to detect Aβ deposits was carried out using methods 
previously described (Guo et al., 2010). Briefly, cryostat sections approximately 16 microns 
thick were cut from paraformaldehyde fixed brains. They were treated for 5 min with 88% 
formic acid (Sigma-Aldrich) to enhance Aβ immunostaining. They were then treated for 15 
min with 1% hydrogen peroxide to eliminate endogenous peroxide. This was followed by the 
addition of 5% skimmed milk and 2% normal rabbit serum, to block non-specific 
immunostaining. Sections were incubated with primary antibody overnight at room 
temperature. The primary antibodies were 6F/3D (Dako; 1:200) or anti-Aβ42 (Mori; 1:2,000). 
This was followed by treatment with rabbit anti-mouse biotinylated IgG (Dako; 1:2000) for 
1-h at room temperature. The sections were then developed by treatment with the ABC 
Vector kit (1:2000) for 1 h, followed by incubation in 0.01% 3,3 diaminobenzidine (DAB, 
Sigma, St Louis MO) containing 1% nickel ammonium sulfate and 0.001% hydrogen 
peroxide. After development of a deep purple color, the sections were washed and mounted. 
 
3. Results 
 Fig. 1 shows the in vitro LTP of fEPSPs in the CA1 region of hippocampal slices. They 
were unaffected following the application of 20 µM Bex. Control LTP was 162.2 ± 8.9% 
after DMSO application, compared to an LTP of 165.1 ± 12.2% after Bex application. Fig. 2 
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shows that Bex was also ineffective in reducing the deficit in LTP caused by application of 
7PA2 CM to hippocampal slices. Following HFS of the Schaffer collaterals, control LTP of 
181.8 ± 9.2% of baseline fEPSP amplitude was unaffected by administration of CHO CM, 
with LTP of 171.6 ± 3.0% of baseline. However, in the presence of 7PA2 CM the amplitude 
of fEPSPs following HFS was reduced to 108.7 ± 8.2% of baseline. This deficit in LTP was 
unaffected following co-incubation of 7PA2 CM with Bex, the magnitude of LTP amounting 
to 101 ± 2.4%. 
 
 
Fig. 1. Effect of Bex (20 µM) administration on fEPSP amplitude over time (left), and LTP at 50-60 min (right). 
Data are presented as mean±SEM. 
 
None of the rats in the group injected s.c. with 15 mg/kg Bex produced sufficient operant 
output for analysis in the experimental chambers (a marked degree of general lethargy was 
also observed for these rats while in their home cages). Consequently, the behavioral analysis 
incorporating s.c. injection of Bex at 2.5, 5, and 10 mg/kg indicated that statistically there 
was a significant overall treatment effect on lever-switching errors (F5,71=2.812, p=0.02; Fig. 
3). The group injected i.c.v. with 7PA2 CM and injected s.c. with vehicle exhibited 
significantly more lever-switching errors than the group injected i.c.v. with CHO CM and  
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Fig. 2. Effect of Bex (20 µM) administration on deficits in LTP induced by 7PA2 CM. Shown are fEPSP 
amplitude over time (top left), LTP at 50-60 min (bottom left), and typical traces from a single experiment per 
group set (right). Data are presented as mean±SEM. **P<0.0001 indicates significant differences compared to 
CHO CM + vehicle. 
 
injected s.c. with vehicle (p<0.03). This confirmed the behavioral deficit induced following 
i.c.v. 7PA2 CM injections. However, there were no significant differences in lever-switching 
errors between the i.c.v. 7PA2 CM injected group given s.c. vehicle (DMSO) injection and 
the i.c.v. 7PA2 CM injected groups given s.c. Bex injections at 2.5, 5, and 10 mg/kg 
(p’s>0.5). In fact, s.c. Bex administration dose-dependently increased the effect size of lever-
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switching errors (p=0.04, p=0.03, p=0.001), suggesting that Bex might be dose-dependently 
increasing the behavioral deficit rather than decreasing it. 
 
 
Fig. 3. Effect of Bex administration on i.c.v. 7PA2 CM-induced lever switching errors. Data are presented as 
mean+SEM. *P<0.05 indicates significant differences CHO CM + vehicle as compared to the 7PA2 CM + 
vehicle, 2.5 mg/kg, 5 mg/kg and 10 mg/kg Bex. 
 
With respect to incorrect lever perseverations, there was a significant overall treatment 
effect (F5,71=2.538, p<0.03; Fig. 4). The group injected i.c.v. with 7PA2 CM and injected s.c. 
with vehicle exhibited significantly more incorrect lever perseverations than the group 
injected i.c.v. with CHO CM and injected s.c. with vehicle (p<0.028). However, there were 
no significant differences in incorrect lever perseverations between the i.c.v. 7PA2 CM 
injected group given s.c. vehicle (DMSO) injection and the i.c.v. 7PA2 CM injected groups  
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Fig 4. Effect of Bex administration on i.c.v. 7PA2 CM-induced incorrect lever perseverations. Data are 
presented as mean+SEM. *P<0.05 indicates significant differences CHO CM + vehicle as compared to the 
7PA2 CM + vehicle, 2.5 mg/kg, 5 mg/kg and 10 mg/kg Bex. 
 
given s.c. Bex injections at 2.5, 5, and 10 mg/kg (p’s>0.5). And again, s.c. Bex dose-
dependently increased the effect size (p=0.04, p=0.02, p=0.001). 
Fig. 5 shows the results of the water maze test performed on the B6SJL mice. All mice 
improved their performance with training. However there was no significant improvement in 
escape latency of Bex fed mice compared with control mice. In fact they performed worse in 
60 seconds. In the spatial memory test for platform location, no improvement of Bex fed 
mice was observed.  Fig. 6 shows typical immunohistochemical results of Abeta deposits in 
control and Bex fed mice. They show extensive deposits in both control and Bex fed mice 
with no evident sparing by Bex feeding. The numbers of deposits were counted in  
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Fig 5. Water-maze behavioural testing in Bex treated and control (non-Bex treated) B6SJL transgenic mice. 
 
representative fields to give a semi-quantitative assessment of the deposits. The plaques were 
counted by computer-aid program Image J. The number detected with the 6F/3D antibody 
were:  Bex:1306+/-211, CTL: 1397+/-162. The number detected with the anti-Aβ42 was: Bex: 
941+/-143, CTL: 879+/-105. 
 
4 Discussion 
Cramer and colleagues (2013) reported that oral administration of Bex in Tg mice 
produced enhanced clearance of soluble Aβ within hours. They reported that Aβ plaques 
were reduced by more than 50% within 72 h, and that there was rapid reversal of cognitive 
deficits and improved neural circuit function. Even though four independent research groups 
(Fitz et al., 2013; Veeraraghavalu et al., 2013; Price et al., 2013; Tesseur et al., 2013) could 
not fully reproduce these findings, Landreth and colleagues (2013) responded that the overall 
findings of these independent groups replicated and validated the central conclusions of the 
Cramer et al. (2013) paper. 
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Fig. 6. Immunostained sections illustrating plaque accumulation and plaque counts in the cerebral cortex of Bex 
treated and control (non-Bex treated) B6SJL transgenic mice. Bex treatment was commenced at 6-7 weeks of 
age and continued for 48 days. Immunostaining was with 6F3D which recognizes Aβ40 and Aβ42, and a specific 
Aβ42 antibody which recognizes only the latter peptide. There was no observable effect of Bex.   
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However, none of the independent research groups investigated the electrophysiological 
effects of Bex. LTP provides an experimental representation of memory at the level of the 
synapse when applied to hippocampal synaptic events (Bliss and Collingridge, 1993). 
Moreover, operant behavior analytical techniques are highly sensitive (Skinner, 1963). The 
rat offers a greater brain area for the collection of detailed electrophysiological data, and 
historically rats have been the rodent of choice where behavioral effects have been important 
(e.g., Ferster and Skinner, 1957). Also, the rat has been first choice when models 
incorporating accurate behavioural measurement relative to pharmacological manipulations 
have been a crucial area of investigation (e.g., Ferster and Skinner, 1957; Wells and Carter, 
2001; Cenci et al., 2002). For these reasons, our study used normal rats for the measurement 
of electrophysiological and behavioral effects following Bex administration. We found no 
beneficial effects of Bex, even at high s.c. doses. 
Cramer et al. (2013) also reported that Bex restored cognition and memory in APP/PS1 
mice, as assessed using a contextual fear conditioning task, when administered for 7 days at 
the 6 and 11 month stages of plaque pathogenesis, and when administered for 90 days and 
analysed when the mice were 9 months old, and also in APPPS1-21 mice at 7-8 months 
following Bex administration for 20 days. They also reported that APP/PS1 mice 
administered with Bex for 90 days, and APPPS1-21 mice administered with Bex for 20 days 
exhibited enhanced performance when assessed using a water maze task.  
In contrast to these findings, we found no beneficial effects of Bex in a water-maze test 
using the B6SJL mouse model of AD (Fig. 5). To enhance the possibility of a favorable 
effect, the high oral dose of 100 mg/kg/day was employed and the dose extended to 48 days 
of administration. This negative finding is consistent with our observation that Bex had no 
ameliorative effect on the accumulated deposition of Aβ deposits (Fig. 6). Again, to enhance 
the possibility of a positive effect, Bex administration was commenced at the time when 
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deposits first start to accumulate. By adopting this approach, any preventative effect of Bex 
administration should have been apparent. 
Bex is not without side effects in humans, according to its Federal Drug Administration 
(FDA) approval status (Lowednthal et al., 2012). The FDA cautions that Bex administration 
to humans causes lipid abnormalities, alters the action of insulin in diabetic patients, and is 
associated with hypothyroidism, leukopenia, elevated liver function values, and an increased 
risk for acute pancreatitis. Consequently, the potential value of Bex administration for the 
management of AD, using the application of varying pre-clinical models, is a matter of 
significant importance prior to the advocacy of this drug for clinical trials in humans 
suffering from AD. The reported results, employing two varying rodent models of AD, 
indicate negative effects on electrophysiological and behavioral outcomes in the rat, and 
indicate no positive effect on behavior or histology using an aggressive model of AD in the 
Tg mouse. In conclusion, the results of the pre-clinical animal studies reported here, proffer 
no support with respect to the putative therapeutic effects of Bex in human clinical trials. 
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